Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Multiple Myeloma cancer. Section View Of The Bone Marrow. BSIP/UIG Via Getty Images
Doctors at the University of Pennsylvania will soon utilize the gene-editing tool CRISPR to try to combat cancer, per the MIT Tech Review.
Why it matters: The trial combines gene-editing and immunotherapy, two promising areas of medical research. There is a lot of anticipation about human trials involving CRISPR but there have been delays.
The details: The study will reportedly involve 18 patients with multiple myeloma, sarcoma, and melanoma cancers. The researchers plan to modify the patient's immune cells to make them better at finding and attacking the cancer. By modifying the cells outside of the body, and then infusing them back into the patient's blood, the researchers hope to avoid some of CRISPR's potential side-effects. It is still unclear when the trial will start.